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http://dx.doi.org/10.1016/j.jmii.2013Background: Emerging carbapenem resistance among Acinetobacter baumannii clinical iso-
lates is a worldwide problem. Infections caused by A. baumannii are increasing and demon-
strate high mortality rates. This study aimed to establish a nationwide surveillance of
antimicrobial susceptibility, carbapenemase genes, and clonal relationships of A. baumannii
clinical isolates in Taiwan.
Methods: Clinical isolates of Acinetobacter calcoaceticuseA. baumannii (ACB) complex
collected by the Taiwan Surveillance of Antimicrobial Resistance-V program between July
2006 and September 2006 were used in this study. Genospecies identification was verified by
16S-23S rRNA intergenic-spacer sequences. Carbapenemase genes were detected by polymer-
ase chain reaction. Pulsed-field gel electrophoresis and multilocus sequence typing (MLST) was
applied for identification of clonal relationships.
Results: Among the 151 ACB-complex isolates collected, 134 (88.7%) were A. baumannii, 12
(8.0%) were A. pittii, and five (3.3%) were A. nosocomialis. A. baumannii isolates showed
higher resistance rates to ciprofloxacin, amikacin, and ampicillin/sulbactam than A. pittii or
A. nosocomialis (all p < 0.001). The most commonly detected carbapenemase genes weret of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100,
tw (S.-C. Chang).
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A. baumannii clinical isolates in Taiwan 325blaOxA-51 (n Z 135), followed by blaOxA-24 (n Z 4), blaOxA-23 (n Z 2), and blaOxA-58 (n Z 1).
Three major A. baumannii clones were found throughout Taiwan, and showed significantly
higher resistance rates to ciprofloxacin, amikacin, and ampicillin/sulbactam than the other
A. baumannii isolates (100% vs. 68.7%, p < 0.001; 98.4% vs. 61.5%, p < 0.001; and 66.7% vs.
39.8%, p Z 0.004; respectively). MLST showed that these major clones were sequence type
2 and belonged to international clonal complex 2.
Conclusion: Our results demonstrate clonal spreading of A. baumannii in Taiwan hospitals and
that these clones were more resistant to many antimicrobial agents. Efforts to prevent and
control A. baumannii colonization/infections and prudent use of antibiotics to reduce antimi-
crobial selective pressure should be emphasized.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acinetobacter baumannii is a major emerging pathogen
causing healthcare-associated infections.1 Carbapenem is
the drug of choice for managing A. baumannii infections2;
however, the occurrence of carbapenem resistance in A.
baumannii (CRAB) isolates is increasing worldwide,3 ranging
from 10% to 70% depending on the country or region.2
Acinetobacter genospecies 1 (A. calcoaceticus), geno-
species 2 (A. baumannii), genospecies 3 (A. pittii), and
genospecies 13TU (A. nosocomialis) are phenotypically
similar and are referred to as the A. calcoaceticuseA.
baumannii (ACB) complex strains.4 Genospecies 1 is
considered an environmental pathogen, as opposed to
causing healthcare-associated infections,5 and A. bau-
mannii causes more severe diseases than the other geno-
species.6 Therefore, surveillance and determination of the
different genospecies among the ACB-complex strains in
areas with high ACB-complex prevalence rates is important.
In this study, clinical isolates collected from the Taiwan
Surveillance of Antimicrobial Resistance (TSAR-V) study7
were analyzed. We aimed to establish nationwide epide-
miology data on carbapenem resistance and carbapene-
mase genes and also to determine the disease burden of the
different genospecies. In Taiwan, there is an increasing rate
of carbapenem resistance. However, whether there were
clonal spread was not identified. Pulsed-field gel electro-
phoresis (PFGE) was used for typing the A. baumannii iso-
lates8 in order to identify if there were dominant clones
circulating in Taiwan. Multilocus sequence typing (MLST) 9
was used to determine the relationship between the in-
ternational lineages and the isolates in Taiwan.Methods
Hospital setting and bacterial isolates
The Taiwan Surveillance of Antimicrobial Resistance (TSAR)
program was initiated in 1998 by the National Health
Research Institutes, Taiwan, to monitor the trends and
spectrum of antimicrobial resistance in Taiwan. The pro-
gram collected nonduplicate sequential clinical isolates
from inpatients and outpatients from 25 medical centers
and regional hospitals around Taiwan over a 3-month period
every 2 years. The 25 participating hospitals included ninemedical centers and 16 regional hospitals; seven were
located in northern Taiwan, eight in western Taiwan, seven
in southern Taiwan, and three in eastern Taiwan. In this
study, 151 nonduplicate ACB-complex isolates of various
clinical specimens from the 25 hospitals participating in the
TSAR program from July 2006 to September 2006 (TSAR-V)
were collected.7
This research conformed to the Helsinki Declaration and
local legislation. The samples were taken as part of stan-
dard care. The Institutional Review Board of National
Taiwan University Hospital waived the investigation process
according to the local legislation since all the samples were
analyzed anonymously and only bacteria isolates were
examined.
Bacterial identification
ACB-complex strains were identified using biochemical
methods.10 Genospecies were identified according to the
sequence of the 16Se23S rRNA gene intergenic spacer re-
gion, as previously described.11
Susceptibility testing
Minimum inhibitory concentrations (MICs) of amikacin,
ciprofloxacin, imipenem, ampicillin/sulbactam, tigecy-
cline, and colistin were determined using agar dilution
methods. Susceptibility was interpreted according to the
criteria of the Clinical and Laboratory Standards Institute.12
The MIC breakpoint for tigecycline susceptibility was based
on the FDA breakpoint for Enterobacteriaceae of 2 mg/L.13
Analysis of carbapenem resistance genes
Bacteria DNA was extracted as previously described.11
Primers used in this study are listed in Table 1.14,15 Met-
allo-b-lactamase genes, blaIMP and blaVIM, and carbapenem
hydrolyzing class D b-lactamase (CHDL) genes, blaOxA-51-
like, blaOxA-58-like, blaOxA-23-like, and blaOxA-24-like, were
detected using polymerase chain reaction methods.16
PFGE and multilocus sequence typing
PFGE of ApaI-digested genomic DNA from each ACB-
complex isolate was performed to detect the
Table 1 Primers used for PCR of the carbapenemase genes
Name Nucleotide sequence (50e30) Location Reference
IMP-A GAA GGY GTT TAT GTT CAT AC blaIMP 14
IMP-B GTA MGT TTC AAG AGT GAT GC blaIMP 14
VIM2004A GTT TGG TCG CAT ATC GCA AC blaVIM 14
VIM2004B AAT GCG CAG CAC CAG GAT AG blaVIM 14
OXA23-F GAT CGG ATT GGA GAA CCA GA blaOxA-23-like 15
OXA23-R ATT TCT GAC CGC ATT TCC AT blaOxA-23-like 15
OXA24-F GGT TAG TTG GCC CCC TTA AA blaOxA-24-like 15
OXA24-R AGT TGA GCG AAA AGG GGA TT blaOxA-24-like 15
OXA51-F TAA TGC TTT GAT CGG CCT TG blaOxA-51-like 15
OXA51-R TGG ATT GCA CTT CAT CTT GG blaOxA-51-like 15
OXA58-F AAG TAT TGG GGC TTG TGC TG blaOxA-58-like 15
OXA58-R CCC CTC TGC GCT CTA CAT AC blaOxA-58-like 15
Table 2 Source of clinical isolates and distribution of
different Acinetobacter baumannii-complex isolates
Source A. baumannii
(n Z 134)
A. pittii
(n Z 12)
A. nosocomialis
(n Z 5)
Blood, n (%) 13 (9.7) 3 (25) 2 (40)
Sputum, n (%) 57 (42.5) 6 (50) 3 (60)
Urine, n (%) 23 (17.2) 0 (0) 0 (0)
Wound pus,
n (%)
24 (17.9) 2 (16.7) 0 (0)
Catheter tip,
n (%)
2 (1.5) 0 (0) 0 (0)
Other, n (%) 15 (11.2) 1 (8.3) 0 (0)
326 Y.-C. Chuang et al.relationships among the clinical isolates.8,17 PFGE patterns
were compared using the software package Gel Compare II
(Applied Maths BVBA, Austin, TX, USA), and unweighted
pair-group mean analysis dendrograms were constructed
from these data. Isolates with a Dice coefficient of
similarity > 80% were considered clusters of possibly
related isolates.17,18
MLST was based on a sequence analysis of the internal
portions of seven housekeeping genes (cpn60, fusA, gltA,
pyrG, recA, rplB and rpoB). The MLST scheme including
amplification and sequencing primers, allele sequences and
sequence types (STs) are available at Institut Pasteur’s
MLSTWeb site (http://www.pasteur.fr/recherche/
genopole/PF8/mlst/references_Abaumannii.html).
Statistical analysis
Categorical data were compared using Fisher’s exact test,
and p < 0.05 was defined as statistically significant. For
multiple comparisons, posthoc analysis using Fisher’s exact
test utilizing a Bonferroni-adjusted a for pair-wise com-
parisons was employed if the initial Fisher’s exact test was
statistically significant. Data were analyzed using Stata
software, version 10 (StataCorp, College Station, TX, USA).
Results
Genospecies distribution of the ACB-complex
isolates
There were a total of 151 clinical ACB-complex isolates
collected, which included 21 isolates (13.9%) from eastern
Taiwan, 38 (25.2%) from northern Taiwan, 55 (36.4%) from
western Taiwan, and 37 (24.5%) from southern Taiwan. Most
of the isolates were collected from sputum (66, 43.7%),
wounds (26, 17.2%), urine (23, 15.2%), or blood (18, 11.9%).
Among the isolates collected, 134 (88.7%) were A. bau-
mannii, 12 (8.0%) were A. pittii, and five (3.3%) were A.
nosocomialis (Table 2).
The antimicrobial susceptibility rates to ciprofloxacin,
amikacin, and ampicillin/sulbactam of A. baumannii iso-
lates were 19.4%, 24.6%, and 50%, respectively. The
A. baumannii isolates showed higher ciprofloxacin,amikacin, and ampicillin/sulbactam resistance than the A.
pittii isolates (all p < 0.001) and also showed higher cip-
rofloxacin and amikacin resistance than the A. nosocomialis
isolates (p < 0.001 and p Z 0.018, respectively) (Table 3).
The susceptibility rates to imipenem, tigecycline, and
colistin of A. baumannii isolates were 80.6%, 77.6%, and
100%, respectively. All A. baumannii isolates showed sus-
ceptibility to colistin (MIC  2 mg/L; Fig. 2A). Among the 26
CRAB isolates, the susceptibility rates to amikacin, cipro-
floxacin, and ampicillin/sulbactam were 0%, 0%, and 23.1%,
respectively. Furthermore, CRAB and carbapenem-
susceptible A. baumannii isolates showed that tigecycline
susceptible rates were 69.2% and 79.6%, respectively, while
the A. pittii and A. nosocomialis isolates all showed 100%
susceptible to tigecycline. However, if an MIC cut-off point
of 1 mg/L was applied,19 the tigecycline susceptibility rates
of CRAB and carbapenem-susceptible A. baumannii isolates
dropped to 15.4% and 36.7%, respectively (Table 4, Fig. 2B).
A. baumannii isolates also showed significantly lower sus-
ceptibility rates to tigecycline than the A. pittii and
A. nosocomialis isolates if an MIC cut-off point of 1 mg/L
was applied (32.1% vs. 91.7%, p < 0.001, and 32.1% vs.
100%, p Z 0.004, respectively).19
Identification of carbapenem-resistance genes
Among the 151 ACB-complex isolates, 135 harbored the
blaOxA-51-like gene. All of the 134 A. baumannii isolates had
Table 3 Antimicrobial susceptibility results for Acinetobacter baumannii-complex isolates
A. baumannii (n Z 134) A. nosocomialis (n Z 5) A. pittii (n Z 12) Overall p
mg/L Susceptible
(%)
mg/L Susceptible
(%)
mg/L Susceptible
(%)
A. baumannii vs.
A. nosocomialis
A. baumannii
vs. A. pittii
Ciprofloxacin
MIC50/MIC90 32/>128 19.4 0.125/0.5 100 0.125/16 75 <0.001 <0.001 <0.001
Range 0.06e>128 0.06e0.5 0.06e16
Amikacin
MIC50/MIC90 >128/>128 24.6 4/>128 80 2/2 100 <0.001 0.018 <0.001
Range 1e>128 2e>128 1e16
Imipenem
MIC50/MIC90 2/8 80.6 0.25/4 100 0.25/0.25 91.7 0.57
Range 0.125e64 0.125e4 0.125e8
Ampicillin/sulbactam
MIC50/MIC90 8/16 50 0.5/4 100 1/1 100 <0.001 0.06 <0.001
Range 0.5e128 0.5e4 0.5e2
Tigecycline
MIC50/MIC90 2/4 77.6 0.25/0.5 100 0.25/0.5 100 0.13
Range 0.125e16 0.125e0.5 0.125e2
Colistin
MIC50/MIC90 1/2 100 2/2 100 1/2 100
Range 0.5e2 0.5e2 0.5e2
MIC Z minimum inhibitory concentration.
A. baumannii clinical isolates in Taiwan 327the blaOxA-51-like gene. In contrast, only one of the five
A. nosocomialis isolates harbored the blaOxA-51-like gene.
Only one isolate was found to have the blaOxA-58-like gene,
which belonged to A. pittii. Two of the A. baumannii iso-
lates had the blaOxA-23-like gene. Three of the A. baumannii
isolates and one of A. pittii isolates had the blaOxA-24-like
gene. None of the isolates were found to harbor the blaIMP
or blaVIM genes (Table 5).
Those isolates with the blaOxA-23-like or blaOxA-24-like
genes had significantly higher resistance rates to imipenem.
Resistance rates of the blaOxA-23-like containing isolates
compared to the non-blaOxA-23-like containing isolates were
100% vs. 16.7% (pZ 0.03), respectively. Resistance rates of
blaOxA-24-like containing isolates compared to non-blaOxA-24-
like containing isolates were 75% vs. 16.2% (p Z 0.02),
respectively.Table 4 Different tigecycline susceptibility rates according to
A. baumannii,
n (%)
A. nosocomial
n (%)
Carbapenem resistant 26 0
Tigecycline susceptible rate a 18 (69.23%) d
Tigecycline susceptible rate b 4 (15.38%) d
Carbapenem susceptible 108 5
Tigecycline susceptible ratea 86 (79.63%) 5 (100%)
Tigecycline susceptible rateb 39 (36.11%) 5 (100%)
a The MIC breakpoint used for tigecycline susceptibility is  2 mg/L
b The MIC breakpoint used for tigecycline susceptibility is  1 mg/LPFGE analysis and antimicrobial susceptibility
among pulsotype clusters
All 151 ACB-complex isolates underwent PFGE analysis.
Among them, 51 isolates belonged to one of three major
pulsotype clusters. In total, 12 (8%) isolates belonged to
pulsotype 4, 26 (17.2%) belonged to pulsotype 5, and 13
(8.6%) belonged topulsotype 7 (Table 6). Isolates belonged to
these three major pulsotypes were found throughout
Taiwan, including 42.8% of isolates from eastern Taiwan, 40%
of isolates from western Taiwan, 15.8% of isolates from
northern Taiwan, and 37.8% of isolates from southern
Taiwan. All isolates of three major clones were A. bau-
mannii. The other 100 ACB-complex isolates were distrib-
uted among 72 other pulsotypes (Fig. 1). All five
A. nosocomialis and 12A. pittii isolates belonged to differentdifferent interpretation cut-points
is, A. pittii,
n (%)
Overall p
A. baumannii vs.
A. nosocomialis
A. baumannii
vs. A. pittii
1
1 (100) 0.99
1 (100) 0.185
11
11 (100%) 0.229
10 (90.91) <0.001 0.008 0.001
.
.
Table 5 Distribution of carbapenem resistance genes among the different genospecies
A. baumannii (n Z 134) A. pittii (n Z 12) A. nosocomialis (n Z 5)
Carbapenem susceptible
(n Z 108)
Carbapenem resistance
(n Z 26)
Carbapenem
susceptible
(n Z 11)
Carbapenem
resistance
(n Z 1)
Carbapenem susceptible
(n Z 5)
blaOxA-51-like 108 (100%)
a 26 (100%)b,c 0 0 1 (20%)
blaOxA-58-like 0 0 0 1 (100%)
d 0
blaOxA-23-like 0 2
b (7.7%) 0 0 0
blaOxA-24-like 1 (0.9%)
a 2c (7.7%) 0 1 (100%)d 0
blaIMP 0 0 0 0 0
blaVIM 0 0 0 0 0
a One isolate had both the blaOxA-51-like and blaOxA-24-like genes.
b Two isolates had both the blaOxA-51-like and blaOxA-23-like genes.
c Two isolates had both the blaOxA-51-like and blaOxA-24-like genes.
d One isolate had both the blaOxA-58-like and blaOxA-24-like genes.
328 Y.-C. Chuang et al.distinct pulsotypes. There were no significant differences in
regional distribution among non-A. baumannii isolates.
The major clones (pulsotypes 4, 5, and 7) of the
A. baumannii isolates showed significantly higher resistance
rates to ciprofloxacin, amikacin, and ampicillin/sulbactam
compared to the other A. baumannii isolates (100% vs.
68.7%, p < 0.001; 98.0% vs. 61.5%, p < 0.001; and 66.7% vs.
39.8%, p Z 0.004; respectively), but they demonstrated
similar resistance rates to imipenem (19.6% vs. 19.3%,
pZ 0.99; Table 6). There were differences in antimicrobial
resistance patterns among the major clones. Pulsotype 4
showed 100% ciprofloxacin and amikacin resistance, which
is significantly higher than other the nonmajor pulsotypes
(other than pulsotypes 4, 5, and 7; p Z 0.032 and
pZ 0.007, respectively). Pulsotypes 5 and 7 also had higher
resistance rates for ciprofloxacin and amikacin compared to
the other nonmajor pulsotypes (p < 0.001, p < 0.001 for
ciprofloxacin and p Z 0.017, p Z 0.004 for amikacin,
respectively). Pulsotype 5 also showed higher ampicillin/
sulbactam resistance (p Z 0.013), and pulsotype 7 exhibi-
ted higher tigecycline resistance (pZ 0.035) relative to the
other nonmajor pulsotypes (Table 6).
MLST
The 51 A. baumannii isolates of themajor clones (pulsotypes
4, 5, and 7) were selected for MLST to find out theTable 6 Antimicrobial resistance of nonmajor clones and circu
Antimicrobial
resistance
Major A. baumannii pulsotypes,
n (%)
N
Pulsotype 4 Pulsotype 5 Pulsotype 7 O
Ciprofloxacin 12 (100%) 26 (100%) 13 (100%) 5
Amikacin 12 (100%) 25 (96.2%) 13 (100%) 5
Ampicillin/sulbactam 7 (58.3%) 18 (69.2%) 9 (69.2%) 3
Imipenem 5 (41.7%) 2 (7.7%) 3 (23.1%) 1
Tigecyclinea 0 (0%) 5 (19.2%) 7 (53.9%) 1
Tigecyclineb 11 (91.7%) 24 (92.3%) 10 (76.9%) 4
Colistin 0 (0%) 0 (0%) 0 (0%)
a The MIC breakpoint used for tigecycline susceptibility is  2 mg/L
b The MIC breakpoint used for tigecycline susceptibility is 1 mg/Lrelationship between major clones in Taiwan and the inter-
national lineages. Fifty isolates were typable, and all had
ST2 (2-2-2-2-2-2-2), which seems to be the typical ST of EU
clone II.20Discussion
In this nationwide surveillance study, we demonstrated
the distribution of the different genospecies of ACB-
complex isolates and also showed the resistance and
the carbapenemase gene distributions among these iso-
lates. There were three dominant clusters of A. bau-
mannii identified, which showed higher antimicrobial
resistance rates for ciprofloxacin, amikacin, and ampi-
cillin/sulbactam and were widely distributed around
Taiwan hospitals. These major clones had ST2 and
belonged to EU clone II.
Isolates of A. baumannii showed an increasing trend of
resistance in Taiwan. TSAR-II in 2000 showed that only 2% of
isolates were resistant to imipenem and the resistance
rates for ciprofloxacin and amikacin were 69% and 63%,
respectively.7 Resistance rates for imipenem, ciprofloxacin,
and amikacin were significantly higher in TSAR-V isolates
collected in 2006 than those of TSAR-II isolates (imipenem
resistance 19.4% vs. 2%, p < 0.001; ciprofloxacin resistancelating major clones of Acinetobacter baumannii in Taiwan
onmajor pulsotypes,
n (%)
p
thers Pulsotype 4
vs. others
Pulsotype 5
vs. others
Pulsotype 7
vs. others
7 (68.7%) 0.032 <0.001 0.017
1 (61.5%) 0.007 <0.001 0.004
3 (39.8%) 0.349 0.013 0.070
6 (19.3%) 0.129 0.231 0.717
8 (21.7%) 0.114 1.000 0.035
6 (55.4%) 0.024 <0.001 0.226
0 (0%)
.
.
A. baumannii clinical isolates in Taiwan 32980.6% vs. 69%, pZ 0.04; and amikacin resistance 75.4% vs.
63%, pZ 0.04; respectively), which indicates the increasing
difficulty of treating patients with ACB-complex infections
in Taiwan.
Distribution of different carbapenem resistant genes in
CRAB isolates has been previously investigated. Other than
blaOxA-51, Yang et al
21 and Chen et al22 showed that blaOxA-
23 was the major CHDL gene carried by CRAB isolates in
their hospitals. Lu et al23 showed that blaOxA-24 and Lee
et al24 showed that blaOxA-58 were the major CHDL genes in
the CRAB isolates in their studies. However, in this
nationwide surveillance of ACB-complex isolates, metallo-
b-lactamase and CHDL genes other than blaOxA-51 were
rarely found. Although not surprising, isolates with both
blaOxA-23-like or blaOxA-24-like and blaOxA-51 genes showed
higher carbapenem resistance, which is consistent with
previous reports.24,25 Nevertheless, among the 26 CRAB
isolates, only two had the blaOxA-23-like gene and two had
the blaOxA-24-like gene, and there were no blaOxA-58-like,
blaIMP, or blaVIM genes identified.Figure 1. Dendrograms based on PFGE types foIn this study, there were three major clusters of
related isolates circulating in Taiwan. These isolates were
more resistant to ciprofloxacin, amikacin, and ampicillin/
sulbactam as well as tigecycline. Horizontal transmission
of antimicrobial resistance genes and clonal spreading
under antimicrobial selection could explain these obser-
vations.9,17 Our findings support clonal spreading as an
important factor influencing antimicrobial resistant A.
baumannii transmission, and this might be the cause of
increased amikacin and ciprofloxacin resistance among
CRAB isolates observed over the past few years.
Tigecycline is considered as an alternative antimi-
crobial agent for treating infections caused by CRAB.2 In
this study, CRAB isolates showed tigecycline suscepti-
bility of 69.2%. If an MIC cut point of 1 mg/L was
applied,2,19 the tigecycline susceptibility rate of CRAB
isolates drop to 15.4% (Table 4, Fig. 2B). Because the
serum levels of tigecycline are low and mean concen-
trations are only 0.63 mg/L,1 our findings infer that
tigecycline monotherapy should be used cautiously,r Acinetobacter baumannii complex isolates.
Figure 1. (continued).
330 Y.-C. Chuang et al.especially in cases of severe infections, such as blood-
stream infections. Furthermore, genospecies identifica-
tion and MIC confirmation should be considered under
these circumstances.
Our study provides the possible explanation that the
increase of the multidrug resistant A. baumannii in Taiwan
may be due to clonal spread. However, there are limita-
tions in this study. First, since the TSAR program was a
microbiology surveillance program, no clinical data were
available. As such, we cannot analyze the clinical impact of
different clusters of A. baumannii isolates, and most of the
isolates were acquired from nonsterile site, so the impact
of resistance on clinical practice should be interpretedcautiously. Second, although our previous study had showed
that ISAba1-blaOxA51, gyrA mutation, and integron were
associated with imipenem, fluoroquinolones, and amino-
glycosides resistance,16,26,27 resistance genes other than
CHDLs, blaIMP, and blaVIM were not evaluated in this study.
Thus, even though possible A. baumannii clonal spreading
with higher resistance was identified, whether the same
resistance mechanism was involved was not clear. Third,
while we included nationwide isolates, including those from
medical centers and regional hospitals, the number of iso-
lates is still relatively small, and might not be representa-
tive of all situations in Taiwan. Further investigations with
more isolates are needed.
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Figure 2. Distribution of minimum inhibitory concentration (MIC) of (A) colistin and (B) tigecycline among carbapenem-resistant
A. baumannii and carbapenem-susceptible A. baumannii isolates.
A. baumannii clinical isolates in Taiwan 331This study demonstrated clonal spreading of dominant A.
baumannii isolates in Taiwan and that these clones were
more resistant to multiple antimicrobial agents. This might
explain the high prevalence of CRAB and the continuing
increase in CRAB infections in Taiwan. As predominant
clusters showed more resistance to various antimicrobial
agents, efforts to prevent and control of A. baumannii in-
fections and prudent use of antibiotics in Taiwan should be
emphasized.Conflicts of interest
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